153 related articles for article (PubMed ID: 37339826)
1. Immune checkpoint inhibitor lichenoid eruption due to pembrolizumab.
McCormick BJ; Zieman D; West-Santos C; Phillips MB
BMJ Case Rep; 2023 Jun; 16(6):. PubMed ID: 37339826
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
4. Resolution of Pembrolizumab-Associated Steroid-Refractory Lichenoid Dermatitis with Cyclosporine.
Fixsen E; Patel J; Selim MA; Kheterpal M
Oncologist; 2019 Mar; 24(3):e103-e105. PubMed ID: 30617087
[TBL] [Abstract][Full Text] [Related]
5. Narrowband ultraviolet B therapy for refractory immune-related lichenoid dermatitis on PD-1 therapy: a case report.
Esfahani K; Henderson Berg MH; Zargham H; Billick R; Pehr K; Redpath M; Roshdy O; Miller WH
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771890
[TBL] [Abstract][Full Text] [Related]
6. Resolution of pembrolizumab-associated lichenoid dermatitis with a single dose of methotrexate.
Varma A; Friedlander P; De Moll EH; Desman G; Levitt J
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621697
[TBL] [Abstract][Full Text] [Related]
7. Digital ulcerative lichenoid dermatitis in a patient receiving anti-PD-1 therapy.
Martínez-Doménech Á; García-Legaz Martínez M; Magdaleno-Tapial J; Valenzuela-Oñate C; Pérez-Pastor G; Pérez-Ferriols A
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738845
[TBL] [Abstract][Full Text] [Related]
8. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
9. PD1 inhibitor induced inverse lichenoid eruption: a case series.
Sethi M; Garg V; Lee JB; Yang S
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423421
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
11. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14
Curry JL; Reuben A; Szczepaniak-Sloane R; Ning J; Milton DR; Lee CH; Hudgens C; George S; Torres-Cabala C; Johnson D; Subramanya S; Wargo JA; Mudaliar K; Wistuba II; Prieto VG; Diab A; Tetzlaff MT
J Cutan Pathol; 2019 Sep; 46(9):627-636. PubMed ID: 30883858
[TBL] [Abstract][Full Text] [Related]
13. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.
Tetzlaff MT; Tang S; Duke T; Grabell DA; Cabanillas ME; Zuo Z; Yao JC; Nagarajan P; Aung PP; Torres-Cabala CA; Duvic M; Prieto VG; Huen A; Curry JL
J Cutan Pathol; 2019 Nov; 46(11):872-877. PubMed ID: 31254410
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns.
Truong K; Chamberlin CV; Kim J; Carlino MS; Araujo RR
Australas J Dermatol; 2024 Mar; 65(2):163-166. PubMed ID: 38009870
[TBL] [Abstract][Full Text] [Related]
15. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
Shen L; Chen H; Wei Q
Front Immunol; 2021; 12():621858. PubMed ID: 33936037
[TBL] [Abstract][Full Text] [Related]
16. Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review.
Kan S; Ren H; Gao Z; Dai E; Liu Y; Yang L; Cai Q
Immunotherapy; 2021 Dec; 13(17):1373-1378. PubMed ID: 34632814
[TBL] [Abstract][Full Text] [Related]
17. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
18. Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis.
Ghiam N; Ojong O; Vasile G; Romanelli P; Kerdel F
Dermatol Online J; 2020 Dec; 26(12):. PubMed ID: 33423430
[TBL] [Abstract][Full Text] [Related]
19. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: A report of two cases and published work review.
Obara K; Masuzawa M; Amoh Y
J Dermatol; 2018 May; 45(5):587-591. PubMed ID: 29352490
[TBL] [Abstract][Full Text] [Related]
20. Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab.
Shah RR; Bhate C; Hernandez A; Ho CH
Dermatol Ther; 2022 May; 35(5):e15432. PubMed ID: 35266258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]